GLP-1 coverage in Quebec

Quebec is unique in Canada in requiring every resident to be covered by prescription drug insurance, either through RAMQ's public plan or an eligible private plan, typically through an employer. Under RAMQ, Ozempic and Rybelsus are covered when prescribed for type 2 diabetes, subject to the plan's usual income-based deductible and coinsurance structure, which is recalculated periodically and varies by age and income bracket.

Because coverage is mandatory rather than optional, most working-age Quebecers are covered through a workplace plan rather than RAMQ directly, with RAMQ acting as the default for those without access to an eligible private plan, including many retirees, students, and self-employed residents.

RAMQ's listings for semaglutide products are tied to the type 2 diabetes indication, and coverage does not extend to weight-loss use, whether that's a Wegovy prescription or an off-label weight-loss prescription for a diabetes-indicated drug. This holds true across every provincial public plan in Canada; none currently reimburses a GLP-1 prescribed specifically for weight management.

RAMQ's formulary and its income-based cost-sharing parameters are reviewed and updated over time, so if your prescription's purpose or your income situation has changed, it's worth confirming your current status with RAMQ rather than assuming last year's coverage still applies.

Because Quebec mandates drug coverage, a larger share of the working population carries an employer or group private plan than in most other provinces, and it's through these plans that GLP-1 weight-loss coverage is most likely to appear. Nationally, about 31% of employer plans now offer some GLP-1 coverage for weight management, though the specific terms, prior authorization requirements, and annual maximums vary by plan.

If you're covered through a workplace plan rather than RAMQ, check your plan's drug list or call your insurer directly, since Quebec's mandatory-coverage rule means many residents may not have looked closely at what their default employer plan actually includes for GLP-1s.

For prescriptions not covered by RAMQ or a private plan, dispensing venue still matters. Costco Pharmacy in Quebec has carried generic semaglutide at approximately $99/mo since the May 2026 launch of Canadian generics from Apotex and Dr. Reddy's; a Costco membership is not required to use the pharmacy counter.

Brand-name pricing at retail pharmacies is considerably higher: Ozempic generally runs $250 to $310/mo, Wegovy $400 to $570/mo, Mounjaro $280 to $550/mo, and Zepbound $435 to $550/mo, before insurance or savings programs are applied.

Quebecers without RAMQ or private coverage for a GLP-1 prescription should first confirm whether generic semaglutide meets their prescriber's clinical needs, since it prices meaningfully below brand equivalents. If your prescription is for diabetes, double-check that you're correctly enrolled in either RAMQ or an eligible private plan, since Quebec's mandatory-coverage structure means uncovered gaps are usually an enrollment issue rather than a formulary exclusion.

Manufacturer savings programs remain available for brand products, including Novo Nordisk's Ozempic savings card and WegovyCare, and Eli Lilly's myMounjaro (about $185/mo with eligible coverage) and LillyConnect (Zepbound copay as low as $25/mo with private insurance). Compounded semaglutide or tirzepatide is not a legal option anywhere in Canada, including Quebec, and isn't a substitute for these routes.